Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP971619.RA_ItCrUlXQGl-ZT-VyZY2D_BNsz3Fkkmyg1nHB2ypGJc130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP971619.RA_ItCrUlXQGl-ZT-VyZY2D_BNsz3Fkkmyg1nHB2ypGJc130_assertion type Assertion NP971619.RA_ItCrUlXQGl-ZT-VyZY2D_BNsz3Fkkmyg1nHB2ypGJc130_head.
- NP971619.RA_ItCrUlXQGl-ZT-VyZY2D_BNsz3Fkkmyg1nHB2ypGJc130_assertion description "[The HF pharmacogenetic literature is still in its very early stages, but there are promising candidate genetic variants that may identify which HF patients are most likely to benefit from beta-blockers and ACE inhibitors and patients that may require additional therapies.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP971619.RA_ItCrUlXQGl-ZT-VyZY2D_BNsz3Fkkmyg1nHB2ypGJc130_provenance.
- NP971619.RA_ItCrUlXQGl-ZT-VyZY2D_BNsz3Fkkmyg1nHB2ypGJc130_assertion evidence source_evidence_literature NP971619.RA_ItCrUlXQGl-ZT-VyZY2D_BNsz3Fkkmyg1nHB2ypGJc130_provenance.
- NP971619.RA_ItCrUlXQGl-ZT-VyZY2D_BNsz3Fkkmyg1nHB2ypGJc130_assertion SIO_000772 22464776 NP971619.RA_ItCrUlXQGl-ZT-VyZY2D_BNsz3Fkkmyg1nHB2ypGJc130_provenance.
- NP971619.RA_ItCrUlXQGl-ZT-VyZY2D_BNsz3Fkkmyg1nHB2ypGJc130_assertion wasDerivedFrom befree-2016 NP971619.RA_ItCrUlXQGl-ZT-VyZY2D_BNsz3Fkkmyg1nHB2ypGJc130_provenance.
- NP971619.RA_ItCrUlXQGl-ZT-VyZY2D_BNsz3Fkkmyg1nHB2ypGJc130_assertion wasGeneratedBy ECO_0000203 NP971619.RA_ItCrUlXQGl-ZT-VyZY2D_BNsz3Fkkmyg1nHB2ypGJc130_provenance.